In-vitro antifungal susceptibility testing of lanoconazole and luliconazole against Aspergillus flavus as an important agent of invasive aspergillosis

Omran, Saeid Mahdavi; Armaki, Mojtaba Taghizadeh; Zarrinfar, Hossein; Hedayati, Mohammad Taghi; Abastabar, Mahdi; Moqarabzadeh, Vahid; Ansari, Saham; Saber, Siamak; Hoseinnejad, Akbar; Miri, Ali; Verweij, Paul E.; Seyedmousavi, Seyedmojtaba

doi:10.1016/j.jiac.2018.07.018

Cited by 15 publications

(13 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study all 38 tested isolates have shown that sensitive to voriconazole with the ECV ≤ 2 µg/ml. Many supportive studies have shown that A. flavus to be sensitive to voriconazole, like Denardi et al and Mahdavi-Omran et al which have reported MIC GM values 0.871 and 0.27 µg/ml respectively (7,11). Moreover, in a study by Borman et al only 0.7% of A. flavus isolates were resistant to voriconazole (10) whereas all tested isolates by Varotto et al were sensitive to voriconazole (35).…”

Section: Discussionmentioning

confidence: 96%

“…Luliconazole was recently shown a potent in vitro activity against Aspergillus species including A. fumigatus (2), A. terreus (5), A. flavus (7) and A. niger complex (34) in comparison with other routine antifungal drugs. However, there is no data about the efficacy of luliconazole on A. flavus with otomycosis sources.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, resistant to amphotericin B in invasive aspergillosis has been reported for different Aspergillus species including A. flavus (21,22). Due to limited information about the activity of luliconazole on A. flavus (7), in the present study we compared the efficacy of luliconazole vs. amphotericin B, voriconazole, and caspofungin against the clinical and environmental strains of A. flavus.…”

Section: Introductionmentioning

confidence: 99%

“…Luliconazole initially available as topical cream (LUZU) 1% for dermatophytosis and solution 10% for onychomycosis (1,3,4). A very low minimum inhibitory concentration (MIC) of luliconazole for dermatophytes, Candida, Fusarium and Aspergillus species has been reported (2,(5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

“…Due to amphotericin B side effects and increased resistance to it, new antifungals for the treatment of disseminated mycosis were developed. During 2-3 past decades, new antifungals including, voriconazole, posaconazole and caspofungin were licensed for the treatment of invasive aspergillosis (7,8). So that, voriconazole was presented as the first-line antifungal for invasive aspergillosis therapy (13,14).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

The high efficacy of luliconazole against environmental and otomycosis Aspergillus flavus strains

Moslem

Mahmoudabadi

2020

IJM

View full text Add to dashboard Cite

Background and Objectives: Luliconazole is currently confirmed for the topical therapy of dermatophytosis. Moreover, it is found that luliconazole has in vitro activity against some molds and yeast species. The aim of the present study was to evaluate the efficacy of luliconazole in comparison to routine used antifungals on clinical and environmental isolates of Aspergillus flavus. Materials and Methods: Thirty eight isolates of A. flavus (18 environmental and 20 clinical isolates) were detected based on morphological and microscopic features and also PCR-sequencing of β-tubulin ribosomal DNA gene. All the isolates were tested against luliconazole, voriconazole, amphotericin B and caspofungin. Minimum inhibitory concentration (MIC), 90 MIC50, MIC isolates. and MIC Geometric (GM) were calculated using CLSI M38-A2 protocol for both environmental and clinical GM Results: Luliconazole with extremely low MIC range, 0.00049-0.00781 μg/mL and MIC 0.00288 μg/mL showed very strong activity against both clinical and environmental A. flavus isolates. Moreover, voriconazole inhibited 100% of isolates at defined epidemiological cutoff values (ECV ≤ 2 µg/ml). 50% and 27.8% of clinical and environmental isolates of A. flavus, were resistant to caspofungin, respectively. Whereas, all the isolates were found to be resistant to amphotericin B. GM Conclusion: The analysis of our data clearly indicated that luliconazole (with MIC 0.00244 µg/ml for clinical and 0.00336 μg/ml for environmental isolates) had the highest in vitro activity against A. flavus strains.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%